Effect of Ranolazine After Deferral of Percutaneous Coronary Intervention by Fractional Flow Reserve (IMWELL3)
Phase of Trial: Phase II
Latest Information Update: 12 Jun 2019
Price : $35 *
At a glance
- Drugs Ranolazine (Primary)
- Indications Angina pectoris
- Focus Therapeutic Use
- Acronyms IMWELL3
- 27 Mar 2017 Status changed from recruiting to discontinued.
- 17 Aug 2015 Status changed from not yet recruiting to recruiting, as reported by ClinicalTrials.gov.
- 07 Oct 2014 Planned initiation date changed from 1 Jun 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.